Dr. Strauss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
7777 Forest Ln
Ste C707
Dallas, TX 75230Phone+1 972-566-3000Fax+1 972-566-3099- Is this information wrong?
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1979
- Baylor University Medical CenterResidency, Internal Medicine, 1974 - 1976
- University of Southern California/LAC+USC Medical CenterInternship, Internal Medicine, 1972 - 1973
- New York University School of MedicineClass of 1972
Certifications & Licensure
- TX State Medical License 1974 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPhase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Lone H Ottesen, Yan Li, Ganesh M Mu...> ;Cancer Chemotherapy and Pharmacology. 2023 Sep 1
- Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Dinko Rekić, Corina Dota, Lone H Ot...> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
- Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.Jason J Luke, Sarina A Piha-Paul, Theresa Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James Strauss, David L Ha...> ;Clinical Cancer Research. 2023 Jul 5
- Join now to see all
Press Mentions
- Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
Hospital Affiliations
- Medical City DallasDallas, Texas
- Texas Health Presbyterian Hospital DallasDallas, Texas
- Parkland HealthDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: